



## **ADVITECH: A SECOND PRECLINICAL STUDY WITH POSITIVE RESULTS FOR WOUND HEALING.**

**TSX VENTURE EXCHANGE: AVI**

**FOR IMMEDIATE RELEASE**

**QUEBEC CITY, QUEBEC — February 14, 2008 —** Advitech Inc. (“Advitech” or the “Company”) (TSX Venture Exchange: AVI) announces today that a second preclinical study conducted by Dr Charles Doillon, M.D, PhD from the Oncology and Molecular Endocrinology department of the Centre de Recherche du Centre Hospitalier de l’Université Laval (“CHUL”) has provided new indications of the wound healing properties of a milk devired fraction originating from the research work on its XP828L and IM technological platforms.

New data reveals that Advitech’s fraction is capable of enhancing biochemical activity of fibroblasts (relative to cell proliferation and collagen synthesis) while preventing physiological phenomena that can result in excessive scaring. This further confirms that this fraction, when used under specific conditions, acts early in the repair process by increasing the number of fibroblasts present in the wound, resulting in the production and deposition of collagen fibres present in the newly formed wound tissue. In addition, the fraction appears to modulate excessive remodelling of collagen fibres during the late phase of the wound repair process.

“This feature would constitute a major advantage in plastic and reconstructive surgery wherein the intention is to limit the amount of scaring. In addition, there appears to be utility for natural products like the fraction generated by Advitech’s platform for these applications” noted Dr Doillon.

Christina Juneau PhD, vice-president R&D at Advitech added, “We now have a more comprehensive R&D program on wound healing and repair in place, which should enable the development of specific fractions that can be used in pharmaceutical applications. We expect to announce new data and results in the second quarter of 2008”.

“Since the first announcement on the positive wound healing application results in October 2007, this has opened new market opportunities for Advitech. The positive results generated by our preclinical program have led us to consider new priorities in our business strategy to capitalize on opportunities created by the wound healing platform. We anticipate issuing an update in our business review in the coming weeks.” commented Renaud Beauchesne, president and chief executive officer.

### **About Wound Healing:**

According to Espicom Business Intelligence Ltd., the global wound care market totalled \$7.2 billion in 2006, with a 10% growth rate. Growth factor based applications for wound-healing represent more than 5% of the market, with an impressive 27% growth rate.

**About Advitech Inc. [www.advitech.com](http://www.advitech.com):**

Advitech is a health sciences and technology company with a mission to discover and commercialize

proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex<sup>®</sup> for the treatment of mild-to-moderate psoriasis.

Advitech has drawn up a research program to develop new applications related to wound healing. This development is derived from both its XP-828L and IM technological platforms.

**About Dermylex<sup>®</sup> [www.dermylex.com](http://www.dermylex.com):**

Dermylex<sup>®</sup>, developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, including a 112-day, multi-center, double-blind, placebo-controlled trial with 84 patients, clinically proved the efficacy and safety of Dermylex<sup>®</sup> for that type of psoriasis. Dermylex<sup>®</sup> is currently available in Canada and the U.S. (as BioDerm, Dermalyx<sup>®</sup>), as well as in France and Belgium (as Psopax<sup>®</sup>).

**-30-**

*This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.*

**For further information, please contact:**

**Advitech Inc.**

Renaud Beauchesne, MBA  
President and Chief Executive Officer  
418-686-7498, ext. 228  
[info@advitech.com](mailto:info@advitech.com)

Serge Comeau  
Investor's relations  
514-862-4160  
[s.comeau@advitech.com](mailto:s.comeau@advitech.com)